No increased risk of severe COVID-19 in asthma treated with biologics


Beyaz S., Erecan E., MUTLU P., ÖZŞEKER Z. F.

EURASIAN JOURNAL OF PULMONOLOGY, cilt.24, sa.2, ss.85-94, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.14744/ejp.2022.9821
  • Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.85-94
  • Anahtar Kelimeler: Asthma, biologic agents, COVID-19, dupilumab, mepolizumab, omalizumab, INFECTION, DISEASE, THERAPY, PATIENT, TMPRSS2, PEOPLE, ACE2
  • Çanakkale Onsekiz Mart Üniversitesi Adresli: Evet

Özet

BACKGROUND AND AIM: Biologics can be used safely for patients with severe asthma during the coronavirus pandemic, but there is still a lack of information regarding their effects during SARS-CoV-2 infection. The aim of this study was to evaluate the impact of biologic therapies on the course of SARS-CoV-2 infection and to assess the outcome of COVID-19 for severe asthmatics in pandemic conditions.